Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FBPPH
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of STELARA 90 mg/ml syringes. The delivery order, issued on January 22, 2026, with an ultimate completion date of February 12, 2026, carries no set-aside designation, indicating the vendor competed in an unrestricted procurement environment. This award represents one of numerous delivery orders issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative.
DMS Pharmaceutical Group operates as a critical supplier within the Department of Defense's pharmaceutical supply chain under the PPV-G GEN V program, a $30.3 billion acquisition strategy that positions the company as one of multiple regional prime vendor contractors. The vendor's primary indefinite delivery contract, valued at $499,999,999 and effective through December 31, 2036, authorizes the issuance of firm fixed-price delivery orders for branded and generic prescription medications, biologics, and medical consumables to support DoD healthcare operations globally. The STELARA delivery represents the company's established capability to supply specialized immunosuppressant biologics to military healthcare facilities, consistent with its demonstrated performance across diverse pharmaceutical product categories.
Quick answers
Who was awarded contract SPE2DR26FBPPH?
SPE2DR26FBPPH was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FBPPH worth?
The government has obligated $16,584 on SPE2DR26FBPPH.
Is contract SPE2DR26FBPPH an order under another contract?
Yes. SPE2DR26FBPPH is a delivery order under SPE2DR25D9309, an indefinite delivery contract.
Was contract SPE2DR26FBPPH competed?
The extent of competition for SPE2DR26FBPPH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award